Login / Signup

Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.

Bruce E StroberA B GottliebP C M van de KerkhofLluis L PuigH BachelezE ChouelaS ImafukuD ThaçiH TanH ValdezP GuptaM KaurV FrajzyngierR Wolk
Published in: The British journal of dermatology (2018)
Tofacitinib has a benefit-risk profile in moderate-to-severe psoriasis consistent with that of other systemic treatments.
Keyphrases
  • clinical trial
  • rheumatoid arthritis
  • high intensity
  • early onset
  • drug induced
  • coronary artery disease
  • ulcerative colitis
  • study protocol
  • phase iii
  • hidradenitis suppurativa